These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 23673281

  • 1. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
    Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD.
    Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3012-9. PubMed ID: 23720216
    [Abstract] [Full Text] [Related]

  • 5. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
    Sengeløv L, Kamby C, Geertsen P, Andersen LJ, von der Maase H.
    Cancer Chemother Pharmacol; 2000 Aug 15; 46(5):357-64. PubMed ID: 11127939
    [Abstract] [Full Text] [Related]

  • 6. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan 15; 32(1):48.e1-8. PubMed ID: 24055428
    [Abstract] [Full Text] [Related]

  • 7. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G.
    Clin Genitourin Cancer; 2013 Dec 15; 11(4):495-500. PubMed ID: 23800847
    [Abstract] [Full Text] [Related]

  • 8. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.
    Clin Genitourin Cancer; 2011 Sep 15; 9(1):27-30. PubMed ID: 21700509
    [Abstract] [Full Text] [Related]

  • 9. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C, Agerbaek M, Von Der Maase H.
    Acta Oncol; 2009 Sep 15; 48(3):411-7. PubMed ID: 18798018
    [Abstract] [Full Text] [Related]

  • 10. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3020-6. PubMed ID: 23720197
    [Abstract] [Full Text] [Related]

  • 11. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
    Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, Nonomura K.
    Eur Urol; 2007 Oct 15; 52(4):1106-13. PubMed ID: 17367917
    [Abstract] [Full Text] [Related]

  • 12. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K, Demura T, Nagamori S, Matsuyama H, Naito K, Nonomura K.
    Cancer Chemother Pharmacol; 2006 Sep 15; 58(3):402-7. PubMed ID: 16416335
    [Abstract] [Full Text] [Related]

  • 13. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 14. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R.
    Lancet Oncol; 2012 Aug 15; 13(8):810-6. PubMed ID: 22819172
    [Abstract] [Full Text] [Related]

  • 15. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.
    Cancer Chemother Pharmacol; 2011 Jul 15; 68(1):177-84. PubMed ID: 20878159
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.
    Cancer; 2005 Oct 15; 104(8):1627-32. PubMed ID: 16138364
    [Abstract] [Full Text] [Related]

  • 17. Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer.
    Santoni M, Crabb SJ, Conti A, Rossi L, Burattini L, Conteduca V, Chau C, Burgio SL, Muzzonigro G, Cascinu S, De Giorgi U.
    Clin Genitourin Cancer; 2015 Jun 15; 13(3):244-9. PubMed ID: 25465492
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Sep 15; 14(9):828-32. PubMed ID: 17760750
    [Abstract] [Full Text] [Related]

  • 19. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA, Zhu F, Herr HW.
    BJU Int; 2010 Aug 15; 106(3):357-61. PubMed ID: 20002665
    [Abstract] [Full Text] [Related]

  • 20. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T, Obara T, Saito M, Kumazawa T, Yuasa T, Matuura S, Tsuchiya N, Satoh S, Habuchi T.
    Hinyokika Kiyo; 2007 Sep 15; 53(9):613-8. PubMed ID: 17933135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.